Tanshinone IIA (Synonyms: Dan Shen ketone)

Name: Tanshinone IIA
Brand: MedChemExpress
SKU: HY-N0135
Rating: 5.0 (36 reviews)

Cat. No.: HY-N0135 Pureza: 99.78%: Ficha de datos
COA

SDS
Instrucciones de manejo
FAQs
Technical Support

Tanshinone IIA (Tan IIA) is one of the main compositions in the root of Salvia miltiorrhiza Bunge. Tanshinone IIA may suppress angiogenesis by targeting the protein kinase domains of VEGF/VEGFR2.

Para uso exclusivo en investigación. No vendemos a pacientes.

No. CAS : 568-72-9

Tamaño	Stock	Cantidad
5 mg	En stock	Estimated Time of Arrival: December 31
10 mg	En stock	Estimated Time of Arrival: December 31
25 mg	En stock	Estimated Time of Arrival: December 31
50 mg	En stock	Estimated Time of Arrival: December 31
100 mg	Obtener un presupuesto
200 mg	Obtener un presupuesto

or Consulta para venta a granel

* Seleccione Cantidad antes de agregar artículos.

This product is a controlled substance and not for sale in your territory.

Revisión del cliente

Based on 36 publication(s) in Google Scholar

Other Forms of Tanshinone IIA:

Tanshinone IIA (Standard) In-stock

36 Publications Citing Use of MCE Tanshinone IIA

Cell Proliferation/Viability Assay

: Tanshinone IIA purchased from MedChemExpress. Usage Cited in: J Transl Med. 2023 Jan 20;21(1):34. [Abstract]; Tanshinone IIA (Tan IIA; 24 h) significantly decreases the cell viability when concentration reaches to 50 µM in bEnd0.3 cells.

: Tanshinone IIA purchased from MedChemExpress. Usage Cited in: Eur J Pharmacol. 2020 Aug 5;880:173140. [Abstract]; Phospho-p65 (p-p65), p65, IL-1β, IL-6, TNF-α, and KLF4 expression in unligated, ligated and ligated + Tan IIA-treated carotid arteries is determined by Western blotting days 21 after carotid artery ligation.

: Tanshinone IIA purchased from MedChemExpress. Usage Cited in: J Pharm Pharmacol. 2018 Oct;70(10):1369-1377. [Abstract]; Tanshinone IIA induces TOV-21G apoptosis. Western blotting is performed with anti-Cleaved caspase 3 or anti-cleaved poly ADP-ribose polymerase (PARP) antibodies. Tubulin is loaded as the loading control.

Recomendaciones destacadas

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Ver todos los productos específicos de isoformas VEGFR:

Ver todas las isoformas

VEGFR1/Flt-1 VEGFR2/KDR/Flk-1 VEGFR3/Flt-4

Actividad biológica
Pureza y Documentación
Referencias
Revisión del cliente

Descripciòn

IC₅₀ & Target

VEGF/VEGFR2^[1]

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	53.2 3 Compound: Tan-IIA	Antiproliferative activity against human A549 cells after 72 hrs by MTT assay Antiproliferative activity against human A549 cells after 72 hrs by MTT assay	[PMID: 30398868]
A549	IC₅₀	2.2 3 Compound: 2a	Antiproliferative activity against human A549 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 34333396]
A549	IC₅₀	2.2 3 Compound: 2a	Antiproliferative activity against human A549 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 34333396]
A549	IC₅₀	6.68 3 Compound: 7; TSA	Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 72 hrs by cell titer glo luminescent assay Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 72 hrs by cell titer glo luminescent assay	[PMID: 35640078]
A549	IC₅₀	53.2 3 Compound: Tan-IIA	Antiproliferative activity against human A549 cells after 72 hrs by MTT assay Antiproliferative activity against human A549 cells after 72 hrs by MTT assay	[PMID: 30398868]
A549	IC₅₀	53.2 3 Compound: Tan-IIA	Antiproliferative activity against human A549 cells after 72 hrs by MTT assay Antiproliferative activity against human A549 cells after 72 hrs by MTT assay	[PMID: 30398868]
A549	IC₅₀	2.2 3 Compound: 2a	Antiproliferative activity against human A549 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 34333396]
A549	IC₅₀	6.68 3 Compound: 7; TSA	Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 72 hrs by cell titer glo luminescent assay Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 72 hrs by cell titer glo luminescent assay	[PMID: 35640078]
A549	IC₅₀	6.68 3 Compound: 7; TSA	Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 72 hrs by cell titer glo luminescent assay Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 72 hrs by cell titer glo luminescent assay	[PMID: 35640078]
AGS	IC₅₀	10 3 Compound: 7, tanshinone iia	Viability of human AGS cells under normoxic conditions after 24 hrs by MTT assay Viability of human AGS cells under normoxic conditions after 24 hrs by MTT assay	[PMID: 17583950]
AGS	IC₅₀	7.53 3 Compound: 7, tanshinone iia	Inhibition of HIF1 activation in human AGS cells assessed as inhibition of hypoxia-induced luciferase expression after 16 hrs by reporter assay Inhibition of HIF1 activation in human AGS cells assessed as inhibition of hypoxia-induced luciferase expression after 16 hrs by reporter assay	[PMID: 17583950]
AGS	IC₅₀	6.8 3 Compound: 7, tanshinone iia	Viability of human AGS cells under hypoxic conditions after 24 hrs by MTT assay Viability of human AGS cells under hypoxic conditions after 24 hrs by MTT assay	[PMID: 17583950]
AGS	IC₅₀	6.8 3 Compound: 7, tanshinone iia	Viability of human AGS cells under hypoxic conditions after 24 hrs by MTT assay Viability of human AGS cells under hypoxic conditions after 24 hrs by MTT assay	[PMID: 17583950]
AGS	IC₅₀	7.53 3 Compound: 7, tanshinone iia	Inhibition of HIF1 activation in human AGS cells assessed as inhibition of hypoxia-induced luciferase expression after 16 hrs by reporter assay Inhibition of HIF1 activation in human AGS cells assessed as inhibition of hypoxia-induced luciferase expression after 16 hrs by reporter assay	[PMID: 17583950]
AGS	IC₅₀	10 3 Compound: 7, tanshinone iia	Viability of human AGS cells under normoxic conditions after 24 hrs by MTT assay Viability of human AGS cells under normoxic conditions after 24 hrs by MTT assay	[PMID: 17583950]
AGS	IC₅₀	10 3 Compound: 7, tanshinone iia	Viability of human AGS cells under normoxic conditions after 24 hrs by MTT assay Viability of human AGS cells under normoxic conditions after 24 hrs by MTT assay	[PMID: 17583950]
BGC-823	IC₅₀	2.8 3 Compound: 10	Anticancer activity against human BGC-823 cells assessed as inhibition of cell viability incubated for 72 hrs by MTT assay Anticancer activity against human BGC-823 cells assessed as inhibition of cell viability incubated for 72 hrs by MTT assay	[PMID: 36332549]
AGS	IC₅₀	6.8 3 Compound: 7, tanshinone iia	Viability of human AGS cells under hypoxic conditions after 24 hrs by MTT assay Viability of human AGS cells under hypoxic conditions after 24 hrs by MTT assay	[PMID: 17583950]
BGC-823	IC₅₀	2.8 3 Compound: 10	Anticancer activity against human BGC-823 cells assessed as inhibition of cell viability incubated for 72 hrs by MTT assay Anticancer activity against human BGC-823 cells assessed as inhibition of cell viability incubated for 72 hrs by MTT assay	[PMID: 36332549]
CWR22R	IC₅₀	6.7 3 Compound: TS-IIA	Cytotoxicity against human 22Rv1 cells incubated for 72 hrs by MTT assay Cytotoxicity against human 22Rv1 cells incubated for 72 hrs by MTT assay	[PMID: 22175694]
CWR22R	IC₅₀	6.7 3 Compound: TS-IIA	Cytotoxicity against human 22Rv1 cells incubated for 72 hrs by MTT assay Cytotoxicity against human 22Rv1 cells incubated for 72 hrs by MTT assay	[PMID: 22175694]
AGS	IC₅₀	7.53 3 Compound: 7, tanshinone iia	Inhibition of HIF1 activation in human AGS cells assessed as inhibition of hypoxia-induced luciferase expression after 16 hrs by reporter assay Inhibition of HIF1 activation in human AGS cells assessed as inhibition of hypoxia-induced luciferase expression after 16 hrs by reporter assay	[PMID: 17583950]
HeLa	IC₅₀	193.2 3 Compound: Tan-IIA	Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay	[PMID: 30398868]
HeLa	IC₅₀	193.2 3 Compound: Tan-IIA	Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay	[PMID: 30398868]
BGC-823	IC₅₀	2.8 3 Compound: 10	Anticancer activity against human BGC-823 cells assessed as inhibition of cell viability incubated for 72 hrs by MTT assay Anticancer activity against human BGC-823 cells assessed as inhibition of cell viability incubated for 72 hrs by MTT assay	[PMID: 36332549]
HeLa	IC₅₀	3.47 3 Compound: 2a	Antiproliferative activity against human HeLa cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Antiproliferative activity against human HeLa cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 34333396]
HeLa	IC₅₀	3.47 3 Compound: 2a	Antiproliferative activity against human HeLa cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Antiproliferative activity against human HeLa cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 34333396]
CWR22R	IC₅₀	6.7 3 Compound: TS-IIA	Cytotoxicity against human 22Rv1 cells incubated for 72 hrs by MTT assay Cytotoxicity against human 22Rv1 cells incubated for 72 hrs by MTT assay	[PMID: 22175694]
Hep 3B2	IC₅₀	> 50 3 Compound: 7, tanshinone iia	Viability of human Hep3B cells under normoxic conditions after 24 hrs by MTT assay Viability of human Hep3B cells under normoxic conditions after 24 hrs by MTT assay	[PMID: 17583950]
Hep 3B2	IC₅₀	6.18 3 Compound: 7, tanshinone iia	Inhibition of HIF1 activation in human Hep3B cells assessed as inhibition of hypoxia-induced luciferase expression after 16 hrs by reporter assay Inhibition of HIF1 activation in human Hep3B cells assessed as inhibition of hypoxia-induced luciferase expression after 16 hrs by reporter assay	[PMID: 17583950]
Hep 3B2	IC₅₀	> 50 3 Compound: 7, tanshinone iia	Viability of human Hep3B cells under hypoxic conditions after 24 hrs by MTT assay Viability of human Hep3B cells under hypoxic conditions after 24 hrs by MTT assay	[PMID: 17583950]
Hep 3B2	IC₅₀	>50 3 Compound: 7, tanshinone iia	Viability of human Hep3B cells under hypoxic conditions after 24 hrs by MTT assay Viability of human Hep3B cells under hypoxic conditions after 24 hrs by MTT assay	[PMID: 17583950]
Hep 3B2	IC₅₀	6.18 3 Compound: 7, tanshinone iia	Inhibition of HIF1 activation in human Hep3B cells assessed as inhibition of hypoxia-induced luciferase expression after 16 hrs by reporter assay Inhibition of HIF1 activation in human Hep3B cells assessed as inhibition of hypoxia-induced luciferase expression after 16 hrs by reporter assay	[PMID: 17583950]
HepG2	IC₅₀	23.9 3 Compound: Tanshinone IIA	Antiproliferative activity against human HepG2 cells Antiproliferative activity against human HepG2 cells	[PMID: 33421712]
HepG2	IC₅₀	65.7 3 Compound: Tan-IIA	Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 30398868]
HepG2	IC₅₀	23.85 3 Compound: TSA	Antiproliferative activity against human HepG2 cells by MTT assay Antiproliferative activity against human HepG2 cells by MTT assay	[PMID: 33601313]
HepG2	IC₅₀	4.91 3 Compound: 2a	Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 34333396]
HepG2	IC₅₀	4.91 3 Compound: 2a	Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 34333396]
HepG2	IC₅₀	23.85 3 Compound: TSA	Antiproliferative activity against human HepG2 cells by MTT assay Antiproliferative activity against human HepG2 cells by MTT assay	[PMID: 33601313]
HepG2	IC₅₀	65.7 3 Compound: Tan-IIA	Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 30398868]
L02	IC₅₀	78.5 3 Compound: Tan-IIA	Antiproliferative activity against human L02 cells after 72 hrs by MTT assay Antiproliferative activity against human L02 cells after 72 hrs by MTT assay	[PMID: 30398868]
L02	IC₅₀	65.29 3 Compound: TSA	Antiproliferative activity against human L02 cells by MTT assay Antiproliferative activity against human L02 cells by MTT assay	[PMID: 33601313]
HeLa	IC₅₀	193.2 3 Compound: Tan-IIA	Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay	[PMID: 30398868]
L02	IC₅₀	65.29 3 Compound: TSA	Antiproliferative activity against human L02 cells by MTT assay Antiproliferative activity against human L02 cells by MTT assay	[PMID: 33601313]
L02	IC₅₀	78.5 3 Compound: Tan-IIA	Antiproliferative activity against human L02 cells after 72 hrs by MTT assay Antiproliferative activity against human L02 cells after 72 hrs by MTT assay	[PMID: 30398868]
HeLa	IC₅₀	3.47 3 Compound: 2a	Antiproliferative activity against human HeLa cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Antiproliferative activity against human HeLa cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 34333396]
Hep 3B2	IC₅₀	6.18 3 Compound: 7, tanshinone iia	Inhibition of HIF1 activation in human Hep3B cells assessed as inhibition of hypoxia-induced luciferase expression after 16 hrs by reporter assay Inhibition of HIF1 activation in human Hep3B cells assessed as inhibition of hypoxia-induced luciferase expression after 16 hrs by reporter assay	[PMID: 17583950]
LNCaP	IC₅₀	0.5 3 Compound: TS-IIA	Cytotoxicity against human LNCAP cells incubated for 72 hrs by MTT assay Cytotoxicity against human LNCAP cells incubated for 72 hrs by MTT assay	[PMID: 22175694]
LNCaP	IC₅₀	0.5 3 Compound: TS-IIA	Cytotoxicity against human LNCAP cells incubated for 72 hrs by MTT assay Cytotoxicity against human LNCAP cells incubated for 72 hrs by MTT assay	[PMID: 22175694]
LNCaP C4-2B	IC₅₀	0.4 3 Compound: TS-IIA	Cytotoxicity against human C4-2B cells incubated for 72 hrs by MTT assay Cytotoxicity against human C4-2B cells incubated for 72 hrs by MTT assay	[PMID: 22175694]
Hep 3B2	IC₅₀	> 50 3 Compound: 7, tanshinone iia	Viability of human Hep3B cells under hypoxic conditions after 24 hrs by MTT assay Viability of human Hep3B cells under hypoxic conditions after 24 hrs by MTT assay	[PMID: 17583950]
LNCaP C4-2B	IC₅₀	0.4 3 Compound: TS-IIA	Cytotoxicity against human C4-2B cells incubated for 72 hrs by MTT assay Cytotoxicity against human C4-2B cells incubated for 72 hrs by MTT assay	[PMID: 22175694]
MCF7	EC₅₀	0.9 3 Compound: Tan II-A	Cytotoxicity against telomerase positive human MCF7 cells after 96 hrs by SRB assay Cytotoxicity against telomerase positive human MCF7 cells after 96 hrs by SRB assay	[PMID: 22044621]
MCF7	IC₅₀	> 5 3 Compound: 2a	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 34333396]
Hep 3B2	IC₅₀	> 50 3 Compound: 7, tanshinone iia	Viability of human Hep3B cells under normoxic conditions after 24 hrs by MTT assay Viability of human Hep3B cells under normoxic conditions after 24 hrs by MTT assay	[PMID: 17583950]
MCF7	ED₅₀	0.38 6 Compound: Tanshinone IIA	Dose required for reduction in cell growth of human breast cancer MCF-7 cell line Dose required for reduction in cell growth of human breast cancer MCF-7 cell line	[PMID: 15509181]
MCF7	EC₅₀	0.9 3 Compound: Tan II-A	Cytotoxicity against telomerase positive human MCF7 cells after 96 hrs by SRB assay Cytotoxicity against telomerase positive human MCF7 cells after 96 hrs by SRB assay	[PMID: 22044621]
MCF7	IC₅₀	7.7935 3 Compound: 2	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 33751939]
HepG2	IC₅₀	23.85 3 Compound: TSA	Antiproliferative activity against human HepG2 cells by MTT assay Antiproliferative activity against human HepG2 cells by MTT assay	[PMID: 33601313]
MCF7	IC₅₀	>5 3 Compound: 2a	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 34333396]
MDA-MB-231	IC₅₀	115.9 3 Compound: Tan-IIA	Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay	[PMID: 30398868]
MCF7	IC₅₀	7.7935 3 Compound: 2	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 33751939]
HepG2	IC₅₀	23.9 3 Compound: Tanshinone IIA	Antiproliferative activity against human HepG2 cells Antiproliferative activity against human HepG2 cells	[PMID: 33421712]
MDA-MB-231	ED₅₀	0.7 6 Compound: Tanshinone IIA	Dose required for reduction in cell growth of human breast cancer MDA-MB-231 cell line Dose required for reduction in cell growth of human breast cancer MDA-MB-231 cell line	[PMID: 15509181]
MDA-MB-231	IC₅₀	7.695 3 Compound: 2	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 33751939]
HepG2	IC₅₀	4.91 3 Compound: 2a	Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 34333396]
MGC-803	IC₅₀	> 5 3 Compound: 2a	Antiproliferative activity against human MGC-803 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Antiproliferative activity against human MGC-803 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 34333396]
MDA-MB-231	IC₅₀	115.9 3 Compound: Tan-IIA	Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay	[PMID: 30398868]
HepG2	IC₅₀	65.7 3 Compound: Tan-IIA	Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 30398868]
MIA PaCa-2	IC₅₀	1.9 3 Compound: 13	Cytotoxicity against human MIAPaCa2 cells after 24 hrs by MTT assay Cytotoxicity against human MIAPaCa2 cells after 24 hrs by MTT assay	[PMID: 21775156]
MDA-MB-231	IC₅₀	7.695 3 Compound: 2	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 33751939]
NCI-N87	IC₅₀	3.1 3 Compound: 10	Anticancer activity against human NCI-N87 cells assessed as inhibition of cell viability incubated for 72 hrs by MTT assay Anticancer activity against human NCI-N87 cells assessed as inhibition of cell viability incubated for 72 hrs by MTT assay	[PMID: 36332549]
MGC-803	IC₅₀	>5 3 Compound: 2a	Antiproliferative activity against human MGC-803 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Antiproliferative activity against human MGC-803 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 34333396]
MIA PaCa-2	IC₅₀	1.9 3 Compound: 13	Cytotoxicity against human MIAPaCa2 cells after 24 hrs by MTT assay Cytotoxicity against human MIAPaCa2 cells after 24 hrs by MTT assay	[PMID: 21775156]
PC-3	EC₅₀	1.2 3 Compound: Tan II-A	Cytotoxicity against telomerase positive human PC3 cells after 96 hrs by SRB assay Cytotoxicity against telomerase positive human PC3 cells after 96 hrs by SRB assay	[PMID: 22044621]
K562	IC₅₀	4.6 3 Compound: TSA	Cytotoxicity against human K562 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay Cytotoxicity against human K562 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay	[PMID: 38889607]
NCI-N87	IC₅₀	3.1 3 Compound: 10	Anticancer activity against human NCI-N87 cells assessed as inhibition of cell viability incubated for 72 hrs by MTT assay Anticancer activity against human NCI-N87 cells assessed as inhibition of cell viability incubated for 72 hrs by MTT assay	[PMID: 36332549]
PC-3	IC₅₀	3.3 3 Compound: TS-IIA	Cytotoxicity against human PC3 cells incubated for 72 hrs by MTT assay Cytotoxicity against human PC3 cells incubated for 72 hrs by MTT assay	[PMID: 22175694]
L02	IC₅₀	65.29 3 Compound: TSA	Antiproliferative activity against human L02 cells by MTT assay Antiproliferative activity against human L02 cells by MTT assay	[PMID: 33601313]
PC-3	EC₅₀	1.2 3 Compound: Tan II-A	Cytotoxicity against telomerase positive human PC3 cells after 96 hrs by SRB assay Cytotoxicity against telomerase positive human PC3 cells after 96 hrs by SRB assay	[PMID: 22044621]
SAOS-2	EC₅₀	> 20 3 Compound: Tan II-A	Cytotoxicity against telomerase negative human Saos2 cells after 96 hrs by SRB assay Cytotoxicity against telomerase negative human Saos2 cells after 96 hrs by SRB assay	[PMID: 22044621]
L02	IC₅₀	78.5 3 Compound: Tan-IIA	Antiproliferative activity against human L02 cells after 72 hrs by MTT assay Antiproliferative activity against human L02 cells after 72 hrs by MTT assay	[PMID: 30398868]
PC-3	IC₅₀	3.3 3 Compound: TS-IIA	Cytotoxicity against human PC3 cells incubated for 72 hrs by MTT assay Cytotoxicity against human PC3 cells incubated for 72 hrs by MTT assay	[PMID: 22175694]
SGC-7901	IC₅₀	250 3 Compound: 10	Anticancer activity against human SGC-7901 cells assessed as inhibition of cell viability incubated for 72 hrs by MTT assay Anticancer activity against human SGC-7901 cells assessed as inhibition of cell viability incubated for 72 hrs by MTT assay	[PMID: 36332549]
LNCaP	IC₅₀	0.5 3 Compound: TS-IIA	Cytotoxicity against human LNCAP cells incubated for 72 hrs by MTT assay Cytotoxicity against human LNCAP cells incubated for 72 hrs by MTT assay	[PMID: 22175694]
LNCaP C4-2B	IC₅₀	0.4 3 Compound: TS-IIA	Cytotoxicity against human C4-2B cells incubated for 72 hrs by MTT assay Cytotoxicity against human C4-2B cells incubated for 72 hrs by MTT assay	[PMID: 22175694]
U-937	IC₅₀	> 5 3 Compound: 2a	Antiproliferative activity against human U-937 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Antiproliferative activity against human U-937 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 34333396]
RAW264.7	IC₅₀	18.17 3 Compound: 1	Inhibition of TRAP activity in RANKL-induced osteoclastogenesis in RAW 264.7 cells Inhibition of TRAP activity in RANKL-induced osteoclastogenesis in RAW 264.7 cells	[PMID: 16872829]
SAOS-2	EC₅₀	>20 3 Compound: Tan II-A	Cytotoxicity against telomerase negative human Saos2 cells after 96 hrs by SRB assay Cytotoxicity against telomerase negative human Saos2 cells after 96 hrs by SRB assay	[PMID: 22044621]
SGC-7901	IC₅₀	250 3 Compound: 10	Anticancer activity against human SGC-7901 cells assessed as inhibition of cell viability incubated for 72 hrs by MTT assay Anticancer activity against human SGC-7901 cells assessed as inhibition of cell viability incubated for 72 hrs by MTT assay	[PMID: 36332549]
U-937	IC₅₀	>5 3 Compound: 2a	Antiproliferative activity against human U-937 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Antiproliferative activity against human U-937 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 34333396]
MCF7	EC₅₀	0.9 3 Compound: Tan II-A	Cytotoxicity against telomerase positive human MCF7 cells after 96 hrs by SRB assay Cytotoxicity against telomerase positive human MCF7 cells after 96 hrs by SRB assay	[PMID: 22044621]
MCF7	ED₅₀	0.38 6 Compound: Tanshinone IIA	Dose required for reduction in cell growth of human breast cancer MCF-7 cell line Dose required for reduction in cell growth of human breast cancer MCF-7 cell line	[PMID: 15509181]
MCF7	IC₅₀	7.7935 3 Compound: 2	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 33751939]
MCF7	IC₅₀	> 5 3 Compound: 2a	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 34333396]
MDA-MB-231	ED₅₀	0.7 6 Compound: Tanshinone IIA	Dose required for reduction in cell growth of human breast cancer MDA-MB-231 cell line Dose required for reduction in cell growth of human breast cancer MDA-MB-231 cell line	[PMID: 15509181]
MDA-MB-231	IC₅₀	115.9 3 Compound: Tan-IIA	Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay	[PMID: 30398868]
MDA-MB-231	IC₅₀	7.695 3 Compound: 2	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 33751939]
MGC-803	IC₅₀	> 5 3 Compound: 2a	Antiproliferative activity against human MGC-803 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Antiproliferative activity against human MGC-803 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 34333396]
MIA PaCa-2	IC₅₀	1.9 3 Compound: 13	Cytotoxicity against human MIAPaCa2 cells after 24 hrs by MTT assay Cytotoxicity against human MIAPaCa2 cells after 24 hrs by MTT assay	[PMID: 21775156]
NCI-N87	IC₅₀	3.1 3 Compound: 10	Anticancer activity against human NCI-N87 cells assessed as inhibition of cell viability incubated for 72 hrs by MTT assay Anticancer activity against human NCI-N87 cells assessed as inhibition of cell viability incubated for 72 hrs by MTT assay	[PMID: 36332549]
PC-3	EC₅₀	1.2 3 Compound: Tan II-A	Cytotoxicity against telomerase positive human PC3 cells after 96 hrs by SRB assay Cytotoxicity against telomerase positive human PC3 cells after 96 hrs by SRB assay	[PMID: 22044621]
PC-3	IC₅₀	3.2 3 Compound: TSA	Cytotoxicity against human PC-3 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay Cytotoxicity against human PC-3 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay	[PMID: 38889607]
PC-3	IC₅₀	3.3 3 Compound: TS-IIA	Cytotoxicity against human PC3 cells incubated for 72 hrs by MTT assay Cytotoxicity against human PC3 cells incubated for 72 hrs by MTT assay	[PMID: 22175694]
RAW264.7	IC₅₀	18.17 3 Compound: 1	Inhibition of TRAP activity in RANKL-induced osteoclastogenesis in RAW 264.7 cells Inhibition of TRAP activity in RANKL-induced osteoclastogenesis in RAW 264.7 cells	[PMID: 16872829]
SAOS-2	EC₅₀	> 20 3 Compound: Tan II-A	Cytotoxicity against telomerase negative human Saos2 cells after 96 hrs by SRB assay Cytotoxicity against telomerase negative human Saos2 cells after 96 hrs by SRB assay	[PMID: 22044621]
SGC-7901	IC₅₀	250 3 Compound: 10	Anticancer activity against human SGC-7901 cells assessed as inhibition of cell viability incubated for 72 hrs by MTT assay Anticancer activity against human SGC-7901 cells assessed as inhibition of cell viability incubated for 72 hrs by MTT assay	[PMID: 36332549]
U-937	IC₅₀	> 5 3 Compound: 2a	Antiproliferative activity against human U-937 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Antiproliferative activity against human U-937 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 34333396]

In Vitro

The anti-tumor effect of Tanshinone IIA includes inhibiting tumor cell proliferation, disturbing tumor cell cycle, promoting tumor cell apoptosis, and inhibiting tumor cell invasion and transfer. Tanshinone IIA has anti-proliferative effects on A549 cells: the IC₅₀ of Tanshinone IIA after 24, 48 and 72 h are 145.3, 30.95 and 11.49 μM, respectively. The CCK-8 assay is used to evaluate the proliferative activity of A549 cells treated with Tanshinone IIA (2.5-80 μM) for 24, 48 and 72 h, respectively. The CCK-8 results show that Tanshinone IIA can significantly inhibit A549 cell proliferation in a dose- and time-dependent manner. Obvious apoptosis and cell growth inhibition of A549 cells are observed after drug treatment for 48 h (concentrations used are approximately IC₅₀ values: Tanshinone IIA 31 μM on A549). Western blotting finds that 48 h exposures to Tanshinone IIA (31 μM) in A549 cells, downregulates expression of VEGF and VEGFR2 protein in both drug treatment groups vs. vehicle^[1].
Tanshinone IIA, one of the most abundant constituents of the root of Salvia miltiorrhiza, protects rat myocardium-derived H9C2 cells against apoptosis. Treatment of H9C2 cells with Tanshinone IIA inhibits angiotensin II-induced apoptosis by downregulating the expression of PTEN (phosphatase and tensin homolog), a tumor suppressor that plays a critical role in apoptosis. Tanshinone IIA inhibits angiotensin II (AngII)-induced apoptosis by downregulating the expression of phosphatase and tensin homolog (PTEN)^[2].
Tanshinone IIA decreases the protein expression of EGFR, and IGFR blocking the PI3K/Akt/mTOR pathway in gastric carcinoma AGS cells^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Tanshinone IIA (10 or 20 mg/kg; p.o) significantly reverses scopolamine-induced cognitive impairments^[1].
Tanshinone IIA (2, 4, 8 mg/kg; i.p.) mediated protective effects on the STZ-induced diabetic nephropathy may be associates with the reduced endoplasmic reticulum stress via attenuating PERK signaling activities^[2].
Tanshinone IIA (3 and 12 mg/kg; i.p.) significantly inhibits the growth of ectopic endometrium^[3].
Tanshinone IIA has been used interchangeably with Tanshinone IIA sulfonate sodium (HY-N1370) in some studies, but there are differences in water solubility, chemical structure, pharmacological activity and pharmacokinetics. When administering to animals, please prepare a solid dispersion or choose to use the sulfonate form of Tanshinone IIA sulfonate sodium (HY-N1370) with better water solubility^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male ICR mice (25–30 g)^[4]
Dosage:	10 or 20 mg/kg
Administration:	P.o.
Result:	Significantly reversed scopolamine-induced cognitive impairments.

Animal Model:	STZ-treated rats^[5]
Dosage:	2, 4, 8 mg/kg
Administration:	I.p.
Result:	Decreased the expression levels of transforming growth factor-beta1, TSP-1, Grp78 and CHOP and attenuated the increase in the protein levels of p-PERK, p-elf2α and ATF-4 from the renal tissues of diabetic rats.

Animal Model:	Female Sprague-Dawley rats (180 -200g)^[6]
Dosage:	3 and 12 mg/kg
Administration:	I.p.
Result:	Significantly inhibited the growth of ectopic endometrium.

Ensayo clínico

Peso molecular

294.34

Fòrmula

C₁₉H₁₈O₃

No. CAS

568-72-9

Appearance

Solid

Color

Orange to red

SMILES

O=C(C1=C2C=CC3=C1CCCC3(C)C)C(C4=C2OC=C4C)=O

Structure Classification

Initial Source

Envío

Room temperature in continental US; may vary elsewhere.

Almacenamiento

Powder	-20°C	3 years
	4°C	2 years

*The compound is unstable in solutions, freshly prepared is recommended.

Solvente y solubilidad

In Vitro:

DMF : 5 mg/mL (16.99 mM; ultrasonic and warming and heat to 60°C)

Ethanol : 1 mg/mL (3.40 mM; ultrasonic and warming and heat to 60°C)

DMSO : 1 mg/mL (3.40 mM; ultrasonic and warming and heat to 80°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	3.3974 mL	16.9872 mL	33.9743 mL
5 mM	0.6795 mL	3.3974 mL	6.7949 mL
10 mM	0.3397 mL	1.6987 mL	3.3974 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.

Calculadora de molaridad
Calculadora de dilución

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% EtOH 90% Corn Oil
Solubility: ≥ 0.1 mg/mL (0.34 mM); Clear solution

This protocol yields a clear solution of ≥ 0.1 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (1.0 mg/mL) to 900 μL Corn oil, and mix evenly.

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 0.5% CMC-Na/0.1% Tween-80 in Saline water
Solubility: 1 mg/mL (3.40 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

*The compound is unstable in solutions, freshly prepared is recommended.

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Pureza y Documentación

Purity: 99.78%

Select Batch:

Ficha de datos (287 KB) SDS (396 KB)

COA (258 KB) HNMR (138 KB) RP-HPLC (221 KB) LCMS (95 KB)

Instrucciones de manejo (2659 KB)

Referencias

[1]. Xie J, et al. The antitumor effect of tanshinone IIA on anti-proliferation and decreasing VEGF/VEGFR2 expression on the human non-small cell lung cancer A549 cell line. Acta Pharm Sin B. 2015 Nov;5(6):554-63. [Content Brief]

[2]. Zhang Z, et al. Tanshinone IIA inhibits apoptosis in the myocardium by inducing microRNA-152-3p expression and thereby downregulating PTEN. Am J Transl Res. 2016 Jul 15;8(7):3124-32. [Content Brief]

[3]. Su CC, et al. Tanshinone IIA decreases the protein expression of EGFR, and IGFR blocking the PI3K/Akt/mTOR pathway in gastric carcinoma AGS cells both in vitro and in vivo. Oncol Rep. 2016 Aug;36(2):1173-9. [Content Brief]

[4]. Zhongyan Zhou, et al. Sodium tanshinone IIA sulfonate: a review of pharmacological activity and pharmacokinetics. Biomedicine & Pharmacotherapy 118 (2019): 109362. [Content Brief]

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

Ethanol / DMSO / DMF	1 mM	3.3974 mL	16.9872 mL	33.9743 mL	84.9358 mL
DMF	5 mM	0.6795 mL	3.3974 mL	6.7949 mL	16.9872 mL
	10 mM	0.3397 mL	1.6987 mL	3.3974 mL	8.4936 mL
	15 mM	0.2265 mL	1.1325 mL	2.2650 mL	5.6624 mL

Tanshinone IIA Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Tanshinone IIA568-72-9Dan Shen ketoneVEGFRVascular endothelial growth factor receptorInhibitorinhibitorinhibit

Please select a local distributor ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Nombre del producto			Requested Quantity *
Nombre del solicitante *			Saludo
Direcciòn del E-mail *			Número de teléfono *
Department			Nombre de la Organizaciòn *
City			Provincia
Country or Region *
Observaciones

Nombre del producto			Lot #
Nombre del solicitante *			Direcciòn del E-mail *
Número de teléfono			Department *
Nombre de la Organizaciòn *			Country or Region *
Observaciones

Name
E-mail *

	Sorry, but the email address you supplied was invalid.

Tanshinone IIA (Synonyms: Dan Shen ketone)

Revisión del cliente

Other Forms of Tanshinone IIA:

Tanshinone IIA Related Antibodies

36 Publications Citing Use of MCE Tanshinone IIA

Recomendaciones destacadas

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Ver todos los productos específicos de isoformas VEGFR:

Actividad biológica

Pureza y Documentación

Referencias

Revisión del cliente

Tanshinone IIA Related Antibodies

Calculadora de molaridad

Calculadora de dilución

Complete Stock Solution Preparation Table

Tanshinone IIA Related Classifications

Keywords:

Productos vistos recientemente:

Revisión del cliente

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report